investigator_user
investigator
user
funding
collaborators
pending
menu
bell
message
arrow_up
arrow_down
filter
layers
globe
marker
add
arrow
close
download
edit
facebook
info
linkedin
minus
plus
save
share
search
sort
twitter
remove
user-plus
user-minus
Sign Up for Updates
Map
Countries
Cancer types
All cancers but non-melanoma skin cancer
Bladder
Brain, nervous system
Breast
Cervix uteri
Colorectum
Corpus uteri
Gallbladder
Hodgkin lymphoma
Kaposi sarcoma
Kidney, renal pelvis and ureter
Larynx
Leukaemia
Lip, oral cavity
Liver and intrahepatic bile ducts
Melanoma of skin
Multiple myeloma and immunoproliferative diseases
Nasopharynx
Non-Hodgkin lymphoma
Non-Melanoma skin cancer
Oesophagus
Other pharynx
Ovary
Pancreas
Prostate
Sarcoma
Stomach
Testis
Thymus
Thyroid
Trachea, bronchus and lung
Specialities
Hematology and hematologic malignancies
Palliative Care
Pathology
Pediatric oncology or childhood cancer
Radiation Oncology
Surgery / Surgical oncology
Blog
About
Login
Project leads
Collaborators
Transgenic Models for Prostate and Breast Cancer
Jeffrey Green
1 Collaborator(s)
Funding source
National Cancer Institute (NIH)
Follow
+ Project
+ Post
+ Event
Info
People
Posts
To use genomic technologies to understand prostate and mammary cancer progression.
Related projects
Peter Blumberg
Molecular Mechanism of Action of Phorbol Ester
Prostate
Marie C. Lee
Development of the Malignancy-Risk Gene Signature Assay for Predicting Breast Cancer Risk
Breast
Carol A Lange
Inducible PTK6 expression drives oncogenic signaling in breast cancer
Breast
Susan L Teitelbaum
Breast Cancer Genomics in Windows of Susceptibility to Endocrine Disruptors
Breast
William Figg
Development of Drugs that Target Prostate Cancer
Prostate
Pathology
Anthony J Koleske
Regulation of Invadopodia Formation in Breast Cancer Cells
Breast
Philip Tofilon
Radiation-induced translational control of gene expression
Breast
Prostate
Radiation Oncology
Gordon Hager
Chromatin Remodeling Proteins
Breast
Fraser Symmans
Development of A Predictive Genomic Diagnostic Test for Survival Benefit from Everolimus (mTOR Inhibitor) Combined with Endocrine Therapy for Metastatic HR+/HER- Breast Cancer
Breast